Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Health-Related QoL Poor Among Myeloma, Pancreatic Cancer Survivors

November 11, 2014
By Leah Lawrence
Article

Survivors of multiple myeloma and pancreatic cancer may have some of the poorest physical health-related quality of life outcomes, according to a new study.

Although researched less, survivors of cancers that occurred at less common sites may also have poor health-related quality of life (HRQOL) outcomes, particularly among survivors of multiple myeloma and pancreatic cancer.

Erin E. Kent, PhD, of the National Cancer Institute, and colleagues used data from the Surveillance, Epidemiology, and End Results (SEER) national cancer registry system and the Medicare Health Outcomes Survey (MHOS) to research HRQOL in more than 16,000 cancer survivors.

“Most studies of HRQOL among cancer patients and survivors have been limited to breast cancer and, to a lesser extent, prostate, colorectal, and lung cancer, and even fewer studies have examined HRQOL among older long-term survivors,” Kent and colleagues wrote in Cancer. “However, much less is known about the HRQOL experiences of individuals with one of the less common malignancies.”

Therefore, in this study, the researchers looked at patients with kidney cancer, bladder cancer, pancreatic cancer, upper gastrointestinal cancer, cancer of the oral cavity and pharynx, uterine cancer, cervical cancer, thyroid cancer, melanoma, chronic leukemia, non-Hodgkin lymphoma, and multiple myeloma. Outcomes of the 36-Item Short Form Health Survey and the Veterans RAND 12-Item Health Survey were examined and compared to individuals without cancer.

Overall, cancer survivors had lower average Physical Component Scores (PCS) than did individuals without cancer. However, Mental Component Scores (MCS) did not greatly differ between the two groups. A utility metric (Short Form 6D/Veterans RAND 6D), which adjusted for chronic conditions and sociodemographic characteristics, was also calculated.

The lowest PCS and MCS scores reported were among survivors of multiple myeloma (31.3 and 48.8) and pancreatic cancer (35.3 and 48). Survivors of multiple myeloma also had the lowest mean Short Form 6D/Veterans RAND 6D score of 0.63, which was 0.10 points different from individuals without cancer.

Bodily pain, Role-Physical, and Vitality were all prominent concerns among survivors of pancreatic cancer and myeloma, with these two cancer type survivors reporting the lowest mean scores for Role-Physical.

“The disease burden, as evidenced by the current study and a few other published reports of multiple myeloma and pancreatic cancer, suggests the need for research to identify factors that contribute to inferior outcomes among respondents with these malignancies,” the researchers wrote.

In addition, the researchers noted that further research was needed in patients with even less common cancers, such as liver cancer, who were not well-represented in the SEER-MHOS databases.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Related Content

We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.

Understanding Predictive Markers Drives Ruxolitinib Usage in Myelofibrosis

Tim Cortese
September 12th 2025
Article

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
September 12th 2025
Podcast

The performance of the latest Shield algorithm underwent validation in an expanded cohort of individuals enrolled on the ECLIPSE study.

New Blood Test Algorithm Shows Sensitivity, Specificity in CRC Screening

Russ Conroy
September 12th 2025
Article

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
September 12th 2025
Podcast

Data from a propensity-matched analysis showed that GLP-1 receptor agonists conferred benefits even among patients with type 2 diabetes.

GLP-1 Agonists Show Therapeutic Benefits in Polycythemia Vera Population

Ryan Scott
September 12th 2025
Article

Chemo/Radiation Did Not Yield Increased Pelvic Malignancies in Rectal Cancer

Chemo/Radiation Did Not Yield Increased Pelvic Malignancies in Rectal Cancer

Tim Cortese
September 12th 2025
Article
Related Content

We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.

Understanding Predictive Markers Drives Ruxolitinib Usage in Myelofibrosis

Tim Cortese
September 12th 2025
Article

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
September 12th 2025
Podcast

The performance of the latest Shield algorithm underwent validation in an expanded cohort of individuals enrolled on the ECLIPSE study.

New Blood Test Algorithm Shows Sensitivity, Specificity in CRC Screening

Russ Conroy
September 12th 2025
Article

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
September 12th 2025
Podcast

Data from a propensity-matched analysis showed that GLP-1 receptor agonists conferred benefits even among patients with type 2 diabetes.

GLP-1 Agonists Show Therapeutic Benefits in Polycythemia Vera Population

Ryan Scott
September 12th 2025
Article

Chemo/Radiation Did Not Yield Increased Pelvic Malignancies in Rectal Cancer

Chemo/Radiation Did Not Yield Increased Pelvic Malignancies in Rectal Cancer

Tim Cortese
September 12th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.